Kythera Biopharmaceuticals LLC
(NASDAQ : KYTH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
0.81%59.961.4%$1550.16m
JNJJohnson & Johnson
0.56%140.340.7%$880.30m
PFEPfizer Inc.
0.71%38.300.9%$769.20m
MRKMerck & Co., Inc.
0.10%88.840.7%$670.35m
ABBVAbbVie, Inc.
0.32%87.002.3%$649.82m
LLYEli Lilly & Co.
-0.14%119.601.1%$340.88m
AZNAstraZeneca Plc
0.13%47.681.2%$136.29m
RETAReata Pharmaceuticals, Inc.
-0.12%199.323.5%$133.57m
GSKGlaxoSmithKline Plc
0.66%45.510.2%$128.61m
NVSNovartis AG
0.34%91.950.2%$128.17m
KRTXKaruna Therapeutics, Inc.
3.35%67.630.0%$101.66m
NVONovo Nordisk A/S
-0.59%56.740.1%$92.77m
SNYSanofi
-0.11%46.030.2%$69.98m
ALLKAllakos, Inc.
-4.63%117.360.0%$64.39m
BHVNBiohaven Pharmaceutical Holding Co. Ltd.
2.05%54.860.0%$38.47m

Company Profile

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.